Abstract：This article reports the clinical characteristics and treatment processes of three cases of mucormycosis occurring after hematopoietic stem cell transplantation in children, along with a review of relevant literature. All three patients presented with chest pain as the initial symptom, and metagenomic next-generation sequencing (mNGS) confirmed the mucycete infection early in all cases. Two patients recovered after treatment, while one succumbed to disseminated infection. mNGS has facilitated early diagnosis and treatment, reducing mortality rates. Additionally, surgical intervention is an important strategy for improving the prognosis of this condition.
LI Yue,ZHOU Xiao-Hui,WANG Xiao-Dong et al. Diagnosis of mucormycosis in three children following hematopoietic stem cell transplantation using metagenomic next-generation sequencing[J]. CJCP, 2025, 27(2): 219-224.
Girmenia C, Raiola AM, Piciocchi A, et al. Incidence and outcome of invasive fungal diseases after allogeneic stem cell transplantation: a prospective study of the Gruppo Italiano Trapianto Midollo Osseo (GITMO)[J]. Biol Blood Marrow Transplant, 2014, 20(6): 872-880. PMID: 24631738. DOI: 10.1016/j.bbmt.2014.03.004.
Valentine JC, Morrissey CO, Tacey MA, et al. A population-based analysis of invasive fungal disease in haematology-oncology patients using data linkage of state-wide registries and administrative databases: 2005-2016[J]. BMC Infect Dis, 2019, 19(1): 274. PMID: 30898090. PMCID: PMC6429824. DOI: 10.1186/s12879-019-3901-y.
Petraitis V, Petraitiene R, Antachopoulos C, et al. Increased virulence of Cunninghamella bertholletiae in experimental pulmonary mucormycosis: correlation with circulating molecular biomarkers, sporangiospore germination and hyphal metabolism[J]. Med Mycol, 2013, 51(1): 72-82. PMID: 22686246. DOI: 10.3109/13693786.2012.690107.
Jeong W, Keighley C, Wolfe R, et al. The epidemiology and clinical manifestations of mucormycosis: a systematic review and meta-analysis of case reports[J]. Clin Microbiol Infect, 2019, 25(1): 26-34. PMID: 30036666. DOI: 10.1016/j.cmi.2018.07.011.
Bao J, Liu C, Dong Y, et al. Clinical manifestations of pulmonary mucormycosis in recipients of allogeneic hematopoietic stem cell transplantation: a 21-case series report and literature review[J]. Can Respir J, 2022, 2022: 1237125. PMID: 35692949. PMCID: PMC9184213. DOI: 10.1155/2022/1237125.
Walsh TJ, Gamaletsou MN, McGinnis MR, et al. Early clinical and laboratory diagnosis of invasive pulmonary, extrapulmonary, and disseminated mucormycosis (zygomycosis)[J]. Clin Infect Dis, 2012, 54 Suppl 1: S55-S60. PMID: 22247446. DOI: 10.1093/cid/cir868.
Cornely OA, Alastruey-Izquierdo A, Arenz D, et al. Global guideline for the diagnosis and management of mucormycosis: an initiative of the European Confederation of Medical Mycology in cooperation with the Mycoses Study Group Education and Research Consortium[J]. Lancet Infect Dis, 2019, 19(12): e405-e421. PMID: 31699664. PMCID: PMC8559573. DOI: 10.1016/S1473-3099(19)30312-3.
Shi Y, Peng JM, Hu XY, et al. Metagenomic next-generation sequencing for detecting Aspergillosis pneumonia in immunocompromised patients: a retrospective study[J]. Front Cell Infect Microbiol, 2023, 13: 1209724. PMID: 38188627. PMCID: PMC10770824. DOI: 10.3389/fcimb.2023.1209724.
Ao Z, Xu H, Li M, et al. Clinical characteristics, diagnosis, outcomes and lung microbiome analysis of invasive pulmonary aspergillosis in the community-acquired pneumonia patients[J]. BMJ Open Respir Res, 2023, 10(1): e001358. PMID: 36828645. PMCID: PMC9972439. DOI: 10.1136/bmjresp-2022-001358.
Roden MM, Zaoutis TE, Buchanan WL, et al. Epidemiology and outcome of zygomycosis: a review of 929 reported cases[J]. Clin Infect Dis, 2005, 41(5): 634-653. PMID: 16080086. DOI: 10.1086/432579.
Muthu V, Agarwal R, Dhooria S, et al. Has the mortality from pulmonary mucormycosis changed over time? A systematic review and meta-analysis[J]. Clin Microbiol Infect, 2021, 27(4): 538-549. PMID: 33418022. DOI: 10.1016/j.cmi.2020.12.035.
Lamoth F, Chung SJ, Damonti L, et al. Changing epidemiology of invasive mold infections in patients receiving azole prophylaxis[J]. Clin Infect Dis, 2017, 64(11): 1619-1621. PMID: 28199491. DOI: 10.1093/cid/cix130.
Groll AH, Pana D, Lanternier F, et al. 8th European conference on infections in leukaemia: 2020 guidelines for the diagnosis, prevention, and treatment of invasive fungal diseases in paediatric patients with cancer or post-haematopoietic cell transplantation[J]. Lancet Oncol, 2021, 22(6): e254-e269. PMID: 33811813. DOI: 10.1016/S1470-2045(20)30723-3.
Badali H, Ca?ete-Gibas C, McCarthy D, et al. Epidemiology and antifungal susceptibilities of mucoralean fungi in clinical samples from the United States[J]. J Clin Microbiol, 2021, 59(9): e0123021. PMID: 34232068. PMCID: PMC8373021. DOI: 10.1128/JCM.01230-21.
Miller MA, Molina KC, Gutman JA, et al. Mucormycosis in hematopoietic cell transplant recipients and in patients with hematological malignancies in the era of new antifungal agents[J]. Open Forum Infect Dis, 2021, 8(2): ofaa646. PMID: 33575424. PMCID: PMC7863870. DOI: 10.1093/ofid/ofaa646.
Kim JH, Benefield RJ, Ditolla K. Utilization of posaconazole oral suspension or delayed-released tablet salvage treatment for invasive fungal infection[J]. Mycoses, 2016, 59(11): 726-733. PMID: 27392814. DOI: 10.1111/myc.12524.
